Aytu Biopharma (AYTU) Non Operating Income (2010 - 2023)

Aytu Biopharma (AYTU) has reported Non Operating Income for 14 consecutive years, with -$6.6 million the latest figure, recorded in Q3 2023.

• On a quarterly basis, Non Operating Income fell 697.65% year-over-year to -$6.6 million in Q3 2023; TTM through Sep 2023 was -$7.8 million, a 525.12% decrease from a year earlier, with the FY2023 full-year figure at $14000.0, down 98.62% from the prior year.
• Non Operating Income was -$6.6 million for Q3 2023 at Aytu Biopharma, down from -$2.6 million in the prior quarter.
• Over five years, Non Operating Income peaked at $5.3 million in Q2 2021 and troughed at -$10.0 million in Q2 2019.
• A 5-year average of -$456507.2 and a median of -$195390.0 in 2019 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income soared 4544.74% in 2019 and sank 697.65% in 2023, its largest moves.
• Over 5 years, Non Operating Income stood at $4.8 million in 2019, then slumped by 183.11% to -$4.0 million in 2020, then soared by 93.49% to -$257000.0 in 2021, then surged by 138.91% to $100000.0 in 2022, then sank by 6716.0% to -$6.6 million in 2023.
• The last three Non Operating Income figures came in at -$6.6 million (Q3 2023), -$2.6 million (Q2 2023), and $1.4 million (Q1 2023), per Business Quant data.